ARS Pharma (SPRY) Gains China Approval for Neffy, Roth Reiterates Buy Rating [Yahoo! Finance]
ARS Pharmaceuticals, Inc. (SPRY)
Company Research
Source: Yahoo! Finance
reiterated its Buy rating on ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) with a price target of $30 on the stock. In other news, on December 29, ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) reported that China's National Medical Products Administration (NMPA) has approved neffy 2 mg, an epinephrine nasal spray, for the emergency treatment of Type 1 allergic reactions, anaphylaxis. The approval covers adults and children who weigh at least 30 kilograms. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) has an exclusive licensing agreement with Pediatrix Therapeutics, giving Pediatrix the exclusive rights to commercialize neffy in China for severe allergic reactions and certain other conditions like chronic spontaneous urticaria. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) will receive a final regulatory milestone payment of $4 million and expects to receive up to $80 million in additional sales-based milestone payments. The company is also entitled to receive tiered royalties in the low double-digit rang
Show less
Read more
Impact Snapshot
Event Time:
SPRY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SPRY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SPRY alerts
High impacting ARS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SPRY
News
- ARS Pharmaceuticals announces NMPA approval for neffy 2 mg [Yahoo! Finance]Yahoo! Finance
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) [Yahoo! Finance]Yahoo! Finance
- neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)GlobeNewswire
- How Recent Developments Are Shaping the Story for ARS Pharmaceuticals According to Analysts [Yahoo! Finance]Yahoo! Finance
- ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
SPRY
Earnings
- 11/10/25 - Miss
SPRY
Sec Filings
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- 1/5/26 - Form 4
- SPRY's page on the SEC website